Boston Scientific (BSX) AI Stock Analysis

• Market Cap: $158.87B
• Dividend Yield: N/A
• Average Volume (3M): 6.10M
• Price to Earnings (P/E): 64.4
• Beta (1Y): 0.79
• Revenue Growth: 21.45%
• EPS Growth: 36.19%
• Country: US
• Employees: 53,000
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Devices
• EPS (TTM): 0.75
• Shares Outstanding: 1,481,751,600
• 10 Day Avg. Volume: 5,993,399
• 30 Day Avg. Volume: 6,095,039
• PEG Ratio: 4.27
• Price to Book (P/B): 6.04
• Price to Sales (P/S): 7.85
• P/FCF Ratio: 49.69
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 9.30
• Enterprise Value/Gross Profit: 14.71
• Enterprise Value/Ebitda: 36.50
• 1Y Price Target: $125.90
• Price Target Upside: 16.48% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 21

• Rating: 79 Outperform
• Price Target: $124.00 ▲(14.72% Upside)

Boston Scientific's strong financial performance and positive earnings call sentiment are major strengths, driving the overall score. While technical indicators are favorable, the high valuation poses a risk. The company's raised guidance and strategic growth in key segments support a positive outlook.

Positive Factors

Earnings Performance

Boston Scientific delivered a standout performance, with net sales growth and organic growth above the high end of the prior guide, supported by strong growth in EP and WATCHMAN.

Growth Outlook

Analyst maintains a Buy rating as BSX is considered to have one of the better growth outlooks in large cap medtech.

Market Position

Management continues to effectively execute on their growth strategy across multiple lines of business, particularly EP and WATCHMAN where FARAPULSE continues to maintain a dominant leadership position.

Revenue and EPS

BSX reported Q2 revenue and EPS ahead of expectations due to strong performance in PFA and Watchman products.

Negative Factors

Product Advisory

Boston Scientific issued a physician advisory letter highlighting calcification risk in older-generation ePTFE-coated ENDOTAK RELIANCE defibrillation leads.

Product Impact

FDA is aware that Boston Scientific has issued a letter notifying affected customers that certain ENDOTAK RELIANCE Defibrillation leads with expanded polytetrafluoroethylene (ePTFE) coated coils may impact shock efficacy and/or require early replacement.

Boston Scientific Business Overview & Revenue Model

Company Description

Boston Scientific Corporation is a global medical technology company that develops, manufactures, and markets a wide range of medical devices. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company operates in various sectors including cardiovascular, rhythm management, endoscopy, urology, and neuromodulation. Boston Scientific's core products include stents, catheters, pacemakers, and other innovative devices designed to improve patient outcomes and enhance the quality of life.

How the Company Makes Money

Boston Scientific generates revenue primarily through the sale of its medical devices across multiple therapeutic areas. The company’s revenue model is primarily based on direct sales to hospitals, healthcare facilities, and clinics, as well as through partnerships with various distributors. Key revenue streams include sales from cardiovascular devices, which encompass coronary and peripheral interventions, as well as rhythm management products such as implantable cardioverter-defibrillators and pacemakers. Additionally, Boston Scientific benefits from recurring revenue through the sale of consumable products and accessories needed for procedures using their devices. The company also invests in research and development to innovate and expand its product offerings, which can lead to increased market share and revenue growth. Strategic partnerships with healthcare providers and co-development agreements with other medical technology firms further enhance its revenue potential by broadening its product portfolio and market reach.

Boston Scientific Financial Statement Overview

Summary

Boston Scientific presents a strong financial profile with consistent revenue growth, solid profitability, and efficient cash flow management. The company's balanced approach between leveraging debt and maximizing equity returns supports its strategic growth initiatives in the medical devices sector. However, attention to further debt reduction could enhance financial resilience.

Income Statement

Boston Scientific has demonstrated robust growth in its revenue, with a notable TTM (Trailing-Twelve-Months) increase of 4.81% compared to the previous year. The company maintains strong gross and net profit margins at 67.15% and 11.57% respectively, indicating efficient cost management and profitability. The EBIT and EBITDA margins are solid at 17.52% and 21.65%, reflecting operational efficiency. Overall, the company shows a positive growth trajectory in the medical devices industry.

Balance Sheet

The balance sheet reflects a healthy financial position with a Debt-to-Equity ratio of 0.51, showing manageable leverage. The Return on Equity (ROE) stands at a strong 9.15%, indicating effective utilization of shareholders' equity. The Equity Ratio is 55.33%, suggesting a stable asset base supported by equity. Overall, the company maintains a strong balance between debt and equity, although there is room for improvement in reducing debt levels.

Cash Flow

Boston Scientific exhibits strong cash flow management with a Free Cash Flow growth rate of 8.62%, indicating improved cash generation. The Operating Cash Flow to Net Income ratio is 1.88, demonstrating the company's ability to convert income into cash efficiently. The Free Cash Flow to Net Income ratio is 1.41, reflecting good cash flow productivity. Overall, the company shows robust cash flow health, supporting its financial stability and operational needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.49B	16.75B	14.24B	12.68B	11.89B	9.91B
Gross Profit	11.69B	10.27B	8.83B	7.71B	7.46B	5.58B
EBITDA	4.71B	3.94B	3.45B	2.74B	2.52B	1.51B
Net Income	2.50B	1.85B	1.59B	698.00M	1.04B	-82.00M
Balance Sheet
Total Assets	41.56B	39.40B	35.14B	32.47B	32.23B	30.78B
Cash, Cash Equivalents and Short-Term Investments	534.00M	414.00M	865.00M	928.00M	1.93B	1.73B
Total Debt	12.03B	11.15B	9.49B	9.28B	9.45B	9.54B
Total Liabilities	18.91B	17.39B	15.61B	14.90B	15.61B	15.45B
Stockholders Equity	22.42B	21.77B	19.28B	17.57B	16.62B	15.33B
Cash Flow
Free Cash Flow	3.31B	2.65B	1.70B	914.00M	1.32B	1.13B
Operating Cash Flow	4.29B	3.44B	2.50B	1.53B	1.87B	1.51B
Investing Cash Flow	-6.76B	-5.69B	-2.57B	-2.01B	-1.60B	-411.00M
Financing Cash Flow	114.00M	1.81B	5.00M	-548.00M	-95.00M	293.00M

Boston Scientific Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 108.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSX, the sentiment is Positive. The current price of 108.09 is above the 20-day moving average (MA) of 105.51, above the 50-day MA of 104.92, and above the 200-day MA of 100.34, indicating a bullish trend. The MACD of 0.93 indicates Negative momentum. The RSI at 62.52 is Neutral, neither overbought nor oversold. The STOCH value of 77.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BSX.

Boston Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	80 Outperform	$119.16B	25.65	9.72%	2.99%	4.98%	22.08%
BSX	79 Outperform	$158.87B	64.36	11.71%	―	21.45%	36.19%
ABT	79 Outperform	$231.38B	16.62	31.01%	1.76%	5.85%	152.28%
EW	78 Outperform	$47.52B	54.76	15.71%	―	-5.23%	-39.83%
SYK	77 Outperform	$149.98B	51.91	14.25%	0.85%	11.36%	-15.66%
DXCM	73 Outperform	$31.57B	54.61	22.83%	―	9.30%	-14.95%
Sector *	51 Neutral	$7.93B	-0.32	-43.43%	2.21%	22.30%	-1.88%

Boston Scientific Corporate Events

Boston Scientific Announces Executive Retirement Plan Update

On August 29, 2025, Boston Scientific announced that Jeffrey B. Mirviss will retire from his position as Executive Vice President and President of Peripheral Interventions, effective December 1, 2025. He will continue as a senior advisor until February 27, 2026, receiving a prorated base salary. The company plans to enter into a Retirement Agreement with Mr. Mirviss, ensuring he receives benefits consistent with the company’s Executive Retirement Plan and other incentive programs.